When a patient’s bone scan falls in the middle range, the conversation that follows matters. Low bone mass, often called osteopenia, is not a disease diagnosis as much as a signal. It tells you fracture risk is worth watching, but it does not automatically mean someone needs a prescription.
That middle ground is where clear counseling helps. The right plan depends on the person in front of you: their age, risk factors, fracture history, and what they are comfortable doing. Screening and care are individualized, not one-size-fits-all.
This piece walks through three practical areas you can share with patients: lifestyle changes that help nearly everyone, medicines for those at higher risk, and a prescription device-assisted approach that some people ask about. The goal is plain language you can use in a clinic visit.
How low bone density is found today
Most bone density testing in the United States relies on central DXA (dual-energy X-ray absorptiometry) at the hip and spine, used alongside a FRAX score that estimates fracture probability. Peripheral tests exist, but central DXA remains the reference point for most management decisions.
When to treat versus monitor
The Bone Health and Osteoporosis Foundation and reviews it cite familiar thresholds: consider pharmacotherapy in osteopenia when FRAX suggests a 10-year hip fracture risk of 3% or higher, or a major osteoporotic fracture risk of 20% or higher.
The American Academy of Family Physicians summarizes a similar picture. People with a T-score of -2.5 or lower, a prior hip or vertebral fracture, or osteopenia that crosses those FRAX thresholds are generally candidates for drug therapy. Everyone else is usually a candidate for a strong lifestyle focus with follow-up.
Lifestyle that reliably helps
Exercise that loads bone safely
The foundation highlights two exercise types for bone: weight-bearing activity, such as walking, stair climbing, or light jogging when appropriate, and muscle-strengthening work with resistance bands or weights. Balance training and fall-prevention cues round out the plan, since a fracture often involves both fragile bone and a fall.
The practical framing for patients is to match the intensity to their risk and comfort. Someone with very low scores may need supervised, lower-impact options rather than high-impact routines. For a broad, patient-friendly refresher, our guide to bone health basics is a useful resource to share.
Nutrition basics
The foundation recommends about 1,200 mg of calcium per day for women 51 and older, and 800 to 1,000 IU of vitamin D per day for adults over 50, counting all sources with a food-first approach. Supplements can fill gaps, but they are not a reason to skip a balanced diet.
Medicines: when and what to consider
For patients who cross treatment thresholds, medication becomes part of the discussion. Keep it collaborative and grounded in their history, preferences, kidney function, dental health, and fracture risk.
First-line options and the drug holiday idea
Oral and IV bisphosphonates are common first-line choices for many people at higher risk. The AAFP notes that clinicians may consider a drug holiday after roughly five years of oral therapy or three years of IV therapy, depending on ongoing risk.
Key cautions
In January 2024, the FDA added a Boxed Warning for Prolia (denosumab) about severe hypocalcemia risk in advanced chronic kidney disease, especially in patients on dialysis. Rare risks such as osteonecrosis of the jaw and atypical femoral fracture also warrant attention, along with routine lab monitoring and dental care. Access has been changing too, with multiple denosumab biosimilars approved in 2025, some with interchangeability designations.
Device-assisted options: where a prescription wearable fits
What the FDA cleared
On January 12, 2024, the FDA granted De Novo classification (Class II) to a wearable vibration belt indicated to reduce the decline in vertebral strength and volumetric bone mineral density in postmenopausal women with osteopenia, defined by a T-score of -1.0 to -2.49. The FDA’s summary notes that fracture risk was not evaluated, benefits appeared only with protocol adherence, and the device is not indicated for osteoporosis.
What the trial found
In a 12-month randomized, sham-controlled trial, adherent users, defined as those completing at least three sessions per week, had significantly less decline in vertebral strength and volumetric bone mineral density than the sham group. No serious device-related adverse events were reported.
Who might discuss it?
This is a prescription option, so clinician oversight is essential. For patients comparing a non-drug adjunct with exercise and nutrition, educational material on Osteopenia treatment can help explain how the wearable vibration device is used under clinician guidance. Present it as one option among several, not a replacement for medication when medication is indicated, and not a fit for osteoporosis.
Monitoring and follow-up
The foundation advises repeating DXA when results would change management, often at one to two years after starting or changing therapy, or when a patient sits near a treatment threshold. Between scans, track adherence, review any falls, and screen for secondary causes of bone loss.
Bringing the plan together
A simple flow keeps the conversation clear. Start by estimating risk, then build lifestyle habits for everyone, add medicines when risk crosses accepted thresholds, and consider a device-based adjunct in select cases where a patient prefers a non-drug route and it fits their profile.
FAQs
Can low bone mass improve with exercise and nutrition?
Lifestyle steps like weight-bearing exercise, resistance training, adequate calcium and vitamin D, and avoiding tobacco can support bone health and reduce fall risk. Results vary by person, so these habits are best viewed as a foundation you build on rather than a guaranteed reversal.
When do clinicians typically start medicines?
Medication usually enters the discussion when fracture risk crosses accepted thresholds, such as a FRAX 10-year hip risk of 3% or higher, a major osteoporotic fracture risk of 20% or higher, a T-score of -2.5 or lower, or a prior fragility fracture. The final call is made together with the patient.
